Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia

Moritz Fürstenau(University of Cologne), Anna‐Maria Fink(University of Cologne), Steffen Dörfel(Onkozentrum Dresden), Lutz Jacobasch(Orthopädische Praxis), Ali Aldaoud(Klinikum Braunschweig), Kirsten Fischer(Düsseldorf University Hospital), Sandra Robrecht(University of Cologne), Ulrich Kaiser(University of Applied Sciences Landshut), Michael Hallek(Integrated Oncology (United States)), Barbara Eichhorst(University of Cologne), Adam Giza(University of Cologne), Christian Maurer(University of Cologne), Michael Koenigsmann, Hanns‐Detlev Harich(Hof University of Applied Sciences), Hartmut Linde, Thomas Stumpf(University of Cologne), Tobias Gaska(Brüderkrankenhaus St. Josef Paderborn), Julia von Tresckow(Essen University Hospital)
American Journal of Hematology
September 30, 2021
10.1002/ajh.26363
Cited by 9

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k